Tirzepatide vs Retatrutide

Tirzepatide (GLP-1 + GIP) is FDA approved and produces ~20% weight loss in pivotal programs. Retatrutide adds glucagon receptor agonism and has now reported a first positive Phase 3 readout (TRIUMPH-4, December 2025).

Here is the full comparison of what you can take today versus what is still investigational. Tirzepatide: GLP-1 + GIP Dual Agonist Tirzepatide was the first dual incretin agonist — hitting both GLP-1 and GIP receptors simultaneously.

GLP-1 suppresses appetite and slows gastric emptying; GIP acts on fat cells and the brain to further reduce food intake and promote energy expenditure. The combination produces more weight loss than any single-agonist GLP-1 drug and earned FDA approval for both type 2 diabetes (Mounjaro) and obesity (Zepbound), plus obstructive sleep apnea.

Retatrutide: GLP-1 + GIP + Glucagon Triple Agonist Retatrutide adds glucagon receptor agonism to the GLP-1/GIP base. Glucagon agonism increases thermogenesis (raises resting metabolic rate), drives hepatic fat oxidation (directly reducing liver fat), and may sustain weight loss by preventing the metabolic adaptation that slows weight loss on other GLP-1 drugs.

This is why retatrutide Phase 2 data showed the largest weight loss ever recorded in an obesity trial.

Feature Tirzepatide Retatrutide

Use Tirzepatide Now If… ✓ You have obesity, T2D, or obstructive sleep apnea and need FDA-approved treatment available today. ✓ You want proven Phase 3 data, not Phase 2 results — tirzepatide has SURMOUNT-1 through -4, with 20%+ weight loss confirmed across large trials.

✓ You have liver disease (MASH/MASLD) — tirzepatide already has strong hepatic fat reduction data (SURMOUNT-NASH trial). ✓ You can access it through insurance, a manufacturer coupon program, or compounding pharmacy at lower cost.

Watch Retatrutide If… ✓ You have severe MASH or advanced metabolic fatty liver disease and the hepatic glucagon mechanism is specifically important to you. ✓ You have plateaued on tirzepatide at dose and want to understand what options may exist when retatrutide becomes available.

✓ You are interested in a thermogenic mechanism — the glucagon-driven increase in resting metabolic rate is a genuinely novel benefit not available in current GLP-1 drugs. ✓ You are in or eligible for the TRIUMPH Phase 3 trials and want access to cutting-edge data.

Choosing between Tirzepatide and Retatrutide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Tirzepatide and Retatrutide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.